Skip to main content
. Author manuscript; available in PMC: 2016 Sep 28.
Published in final edited form as: Nat Med. 2016 Mar 28;22(5):488–496. doi: 10.1038/nm.4070

Figure 2. ROR-γ antagonists inhibit growth of CRPC cells.

Figure 2

(a) Chemical structures of ROR-γ antagonists SR2211, XY018 and XY011.

(b) Cell viability measured by Cell-Titer GLO of C4-2B cells treated with indicated concentrations of enzalutamide (ENZ), ROR-α agonist SR3335 and ROR-γ antagonists XY018, SR2211, XY011 and SR1555 for 4 days. Experiments were performed with three independent experiments and sextuplicate.

(c) C4-2B and 22Rv1 cells were treated with vehicle or indicated concentrations of SR2211 or XY108 or XY011 for 14 days and colony formation was assessed. * p < 0.05, ** p < 0.01, n = 3.

(d) Caspase-3/7 activities in C4-2B and 22Rv1 cells treated with vehicle or indicated ROR-γ antagonists for 3 days. ** p < 0.01, n = 3.

(e) TUNEL-positive apoptotic cells treated with vehicle or ROR-γ antagonists (5 µM) were counted and expressed as percentage of total cells. Data shown are mean percentage of apoptotic cells ± s.d. * p < 0.05, ** p < 0.01, n = 3.

(f) Immunoblotting analysis of indicated proteins in C4-2B cells treated with vehicle or indicated ROR-γ antagonists for 3 days. Representative blots, n = 3.

All data shown above are mean ± s.d. Significance was calculated using Student’s t-test.